Molecular Mechanisms in Anaphylaxis

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (30 December 2022) | Viewed by 4627

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, UAM, 28040 Madrid, Spain
2. Faculty of Medicine and Biomedicine, Alfonso X El Sabio University, 28691 Madrid, Spain
Interests: anaphylaxis; immunology; vascular permeability; endothelium; molecular mechanisms; extracellular vesicles; miRNAs

Special Issue Information

Dear Colleagues,

Anaphylaxis (AX) is the most severe manifestation of allergic disorders, being a systemic hypersensitivity life-threatening reaction that evolves rapidly. Among the most frequent triggers are food, drugs, and hymenoptera venoms. The plethora of features associated with AX confers difficulties in its diagnosis, impairing the ability to adequately treat these severe reactions. Generally, the diagnosis is carried out according to the clinical symptoms, which are common to many other pathologies, so confirmation through in vitro markers and knowledge about their molecular mechanisms is advisable. Mast cells and basophils are recognized as effector cells eliciting the anaphylactic reaction. However, many other cells and mediators are also relevant. Moreover, the release of mediators causes an endothelial barrier breakdown. This fact produces an increase in vascular permeability and a leakage of fluids, which have influence in two decisive and severe factors (hypotension and hypoxia). Thus, the primary purpose of this Special Issue is to collect scientific contributions providing novel insight into the molecular mechanisms of AX.

Dr. Vanesa Esteban
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anaphylaxis
  • molecular mechanisms
  • mast cells
  • vascular permeability
  • food and drug allergies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1823 KiB  
Article
The Hypertensive Effect of Amphotericin B-Containing Liposomes (Abelcet) in Mice: Dissecting the Roles of C3a and C5a Anaphylatoxins, Macrophages and Thromboxane
by Erik Őrfi, László Hricisák, László Dézsi, Péter Hamar, Zoltán Benyó, János Szebeni and Gábor Szénási
Biomedicines 2022, 10(7), 1764; https://doi.org/10.3390/biomedicines10071764 - 21 Jul 2022
Cited by 2 | Viewed by 1925
Abstract
Liposomal amphotericin B (Abelcet) can cause infusion (anaphylactoid) reactions in patients whose mechanism is poorly understood. Here, we used mice to investigate the role of complement (C) receptors and the cellular sources of vasoactive mediators in these reactions. Anesthetized male NMRI and thromboxane [...] Read more.
Liposomal amphotericin B (Abelcet) can cause infusion (anaphylactoid) reactions in patients whose mechanism is poorly understood. Here, we used mice to investigate the role of complement (C) receptors and the cellular sources of vasoactive mediators in these reactions. Anesthetized male NMRI and thromboxane prostanoid receptor (TP) or cyclooxygenase-1 (COX-1)-deficient and wild type C57Bl6/N mice were intravenously injected with Abelcet at 30 mg/kg. Mean arterial blood pressure (MABP) and heart rate (HR) were measured. In untreated mice, Abelcet caused a short (15 min) but large (30%) increase in MABP. C depletion with cobra venom factor (CVF) and inhibition of C5a receptors with DF2593A considerably prolonged, while C3aR inhibition with SB290157 significantly decreased the hypertensive effect. Likewise, the hypertensive response was abolished in COX-1- and TP-deficient mice. CVF caused a late hypertension in TP-deficient mice. Both macrophage depletion with liposomal clodronate and blockade of platelet GPIIb/IIIa receptors with eptifibatide prolonged the hypertensive effect. The early phase of the hypertensive effect is COX-1- and TP-receptor-dependent, partly mediated by C3aR. In contrast, the late phase is under the control of vasoactive mediators released from platelets and macrophages subsequent to complement activation and C5a binding to its receptor. Full article
(This article belongs to the Special Issue Molecular Mechanisms in Anaphylaxis)
Show Figures

Figure 1

10 pages, 1384 KiB  
Article
Characterization of Mast Cells from Healthy and Varicose Human Saphenous Vein
by Katrine T. Callesen, Sofia Mogren, Frida Berlin, Cecilia Andersson, Susanne Schmidt, Lotte Klitfod, Vanesa Esteban, Lars K. Poulsen and Bettina M. Jensen
Biomedicines 2022, 10(5), 1062; https://doi.org/10.3390/biomedicines10051062 - 3 May 2022
Cited by 2 | Viewed by 1926
Abstract
Mast cells (MCs) are distributed in tissues throughout the body and are highly involved in many physiological and pathophysiological processes. The potential and involvement of different MC phenotypes are still not well understood. MCs are present in blood vessel walls, but their specific [...] Read more.
Mast cells (MCs) are distributed in tissues throughout the body and are highly involved in many physiological and pathophysiological processes. The potential and involvement of different MC phenotypes are still not well understood. MCs are present in blood vessel walls, but their specific phenotypic features are unknown. We aimed at characterizing MCs from human saphenous veins for localization, mediator content, and receptor expression. This was done in MCs from both healthy and varicose human saphenous veins (hSV and vSV, respectively). For both vSV and hSV, we found that vein MCs are mainly present in the tunica adventitia (99% MCs in adventitia) and that the population consists of both MCT and MCTC phenotypes (vSV: 55% MCT, hSV: 64% MCT). The vein MCs contained high levels of histamine (vSV: 27 pg/MC, hSV: 55 pg/MC) and tryptase (vSV: 98 pg/MC, hSV: 111 pg/MC), indicating a strong potential for regulatory effects on blood vessels. The receptor expression of FcεRI, MRGPRX2, PTAFR, C3aR, and C5aR was found, even though the percentage of positive cells differed between vSV and hSV MCs. We conclude that vein MCs from the blood vessel wall have a high potential to affect the tissue around them. Full article
(This article belongs to the Special Issue Molecular Mechanisms in Anaphylaxis)
Show Figures

Figure 1

Back to TopTop